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Plasma Iron: Key to Iron Overload and Iron Deficiency 
Anemias
Iron is essential for fundamental metabolic processes in cells 
and organisms. The key to systemic iron supply and homeo-
stasis lies in the regulation of adequate plasma iron levels. 
Iron circulates in plasma bound to the glycoprotein transferrin, 
which has two high-affinity binding sites for Fe(III). Transfer-
rin binding maintains iron in a soluble form, serves as a major 
vehicle for iron delivery into cells (via the transferrin receptor, 
TfR1), and limits the generation of toxic radicals. In humans, 
plasma transferrin is normally about 30% saturated with iron. A 
transferrin saturation <16% indicates iron deficiency, whereas 
>45% saturation is a sign of iron overload. When the saturation 
exceeds 60%, non-transferrin-bound iron begins to accumu-
late in the circulation and to damage parenchymal cells.
The homeostatic system thus has to maintain transfer-
rin saturation at physiological levels, responding to signals 
from pathways that consume iron (such as erythropoiesis) 
and sending signals to the cells that supply iron to the blood 
stream (Figure 1). Iron is released into the circulation from 
duodenal enterocytes, which absorb 1–2 mg of dietary iron 
per day, and from macrophages, which internally recycle 
20–25 mg of iron from senescent erythrocytes. Hepatocytes 
play a dual role in systemic iron metabolism: they are the 
major site of iron storage and they secrete the regulatory hor-
mone hepcidin (Hamp, LEAP1). Hepcidin orchestrates sys-
temic iron fluxes and controls plasma iron levels by binding to 
the iron exporter ferroportin (SLC40A1, Solute carrier family 
40, member 1) on the surface of iron-releasing cells (Figure 1), 
triggering its degradation and hence reducing iron transfer to 
transferrin (Nemeth et al., 2004). Inherited and acquired dis-
orders that perturb hepcidin production consequently cause 
iron deficiency (high hepcidin levels) or iron overload (hepci-
din deficiency).
Assessing the concentration of serum ferritin is a clinically 
useful measure of iron storage. Low serum ferritin levels indi-
cate depleted stores, whereas increased levels may indicate 
iron overload. Inflammatory conditions (or infections, cancer, 
and liver disorders) can also increase serum ferritin. Given its 
clinical utility, it is surprising that the physiological function(s) 
of serum ferritin and its source (that is, whether it is derived 
from damaged cells or actively secreted by a regulated mecha-
nism) still remain to be defined. Serum ferritin is predominantly 
composed of L chain subunits, partially glycosylated, and iron 
poor.
Iron Absorption
Inorganic dietary iron is absorbed at the brush border of duo-
denal enterocytes via the divalent metal transporter 1 (DMT1/
SLC11A2, solute carrier family 11, member 2) (Gunshin et 
al.,1997). Given that iron largely adopts the oxidized state, it 
must first be reduced by the membrane-associated ferrire-
ductase DcytB (Cybrd1). DcytB may not be the only ferrire-
ductase of the apical membrane of enterocytes, as knock-
out mice appear to have normal iron metabolism (see review 
by McKie, 2008). Heme iron is absorbed independently by 
mechanisms that remain uncertain, because the proposed 
transporter SLC46A1 appears to carry mostly folate (Qiu et 
al., 2006). Heme iron is released intracellularly by hemoxyge-
nase, mainly by the inducible hemoxygenase 1 (HOX1) (Fer-
ris et al., 1999). Cytosolic iron can then be exported into the 
circulation by the basolateral iron exporter ferroportin (McKie 
et al., 2000; Donovan et al., 2000). Enterocytic iron export 
through ferroportin requires hephaestin, a multicopper oxi-
dase homologous to ceruloplasmin, which oxidases Fe(II) to 
Fe(III) for loading onto transferrin. Consistent with this func-
tion, hephaestin-deficient mice display iron deficiency ane-
mia with mucosal iron retention.
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Disruptions in iron homeostasis from both iron deficiency and overload account for some of the 
most common human diseases. Iron metabolism is balanced by two regulatory systems, one that 
functions systemically and relies on the hormone hepcidin and the iron exporter ferroportin, and 
another that predominantly controls cellular iron metabolism through iron-regulatory proteins that 
bind iron-responsive elements in regulated messenger RNAs. We describe how the two distinct 
systems function and how they “tango” together in a coordinated manner. We also highlight some 
of the current questions in mammalian iron metabolism and discuss therapeutic opportunities 
arising from a better understanding of the underlying biological principles.
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Because iron cannot be excreted from the organism in a reg-
ulated way, iron absorption represents the critically controlled 
process. Normally, only 1–2 mg of iron per day are absorbed to 
compensate for iron losses, for example by sloughing of intes-
tinal epithelial cells, desquamation of skin and urinary cells, 
blood loss, or sweat. Iron absorption can be enhanced when 
the needs are higher (for example, because of increased eryth-
ropoiesis or pregnancy) and suppressed in iron overload. The 
lack of an active mechanism for iron excretion accounts for 
the development of iron overload when the regulation of iron 
absorption is defective or bypassed (as occurs in blood trans-
fusions).
Iron Utilization: Erythropoiesis
The vast majority of recycled iron (?25 mg/day) is dedicated to 
hemoglobin synthesis. TfR1 mediates erythroid iron acquisition, 
and its expression parallels the maturation of erythroid pro-
genitors. Mouse embryos lacking TfR1 die because of severe 
anemia (and with neurologic abnormalities), whereas Tfr1 hap-
loinsufficiency or dysfunction of other components of the TfR1 
endocytotic cycle (such as DMT1, STEAP3, or EXOC6, see 
below) cause microcytic anemia (characterized by abnormally 
small red blood cells) as a result of defective iron utilization in 
mice; mutations of DMT1 in humans elicit a similar phenotype 
and cause liver iron accumulation (Table S1 available online) 
(see review by Iolascon et al., 2009). A proposed additional 
route of erythroblast iron acquisition is ferritin released from 
macrophages in the so-called “erythroblastic islands” (Leim-
berg et al., 2008). However, the severe iron deficiency anemia 
of both mice and patients with transferrin deficiency (Table S1) 
suggests that this process can at best make a minor contribu-
tion to erythroid iron acquisition.
Erythroblasts not only acquire but also handle large 
amounts of iron. Potentially, iron may be directly transported 
from endosomes into mitochondria by a “kiss-and-run mech-
anism” through a direct contact between both organelles, 
effectively bypassing the cytosol (Sheftel et al., 2007). Iron 
is imported into mitochondria by the inner membrane pro-
tein mitoferrin 1 (Mfrn1/ SLC25A37, solute carrier family 25, 
member 37) (Shaw et al., 2006). This process is facilitated 
by the ABCB10 (ATP-binding cassette, subfamily B, member 
10) protein, which is thought to stabilize Mfrn1 (Chen et al., 
2009). Mfrn2/SLC25A28 may represent the housekeeping 
Mfrn1 homolog.
To coordinate the synthesis of the heme precursor protopor-
phyrin IX with iron availability, δ-aminolevulinic acid synthase 2 
(ALAS2), the erythroid-specific first enzyme of protoporphyrin 
IX synthesis, is posttranscriptionally regulated by iron via the 
iron-responsive element/iron-regulatory protein (IRE/IRP) sys-
tem (see below). Genetic defects in ALAS2 cause sideroblastic 
Figure 1. Regulation of Systemic Iron Homeostasis
Cells involved in systemic iron regulation are shown. Divalent metal transporter 1 (DMT1) at the apical membrane of enterocytes takes up iron from the lumen of 
the duodenum after DCYTB reduces Fe(III) to Fe(II). Ferroportin at the basolateral membrane cooperates with hephaestin that oxidizes Fe(II) to Fe(III). Iron-loaded 
(diferric) transferrin (Tf-Fe2), indicated by red dots, supplies iron to all cells by binding to the transferrin receptor 1 (TfR1) and subsequent endocytosis. TfR1 is 
highly expressed on hemoglobin-synthesizing erythroblasts. Hepatocytes sense transferrin saturation/iron stores and release hepcidin accordingly. Red cell iron is 
recycled by macrophages via ferroportin and the ferroxidase ceruloplasmin. In iron overload (left), high hepcidin levels inhibit ferroportin-mediated iron export by 
triggering internalization and degradation of the complex to reduce transferrin saturation. Hepcidin expression is high. In iron deficiency (right), iron is released by 
ferroportin into the circulation. Hemoglobin-derived heme is catabolized in macrophages by hemoxygenase-1 (HOX1). Hepcidin expression is low.
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anemia (Table S1), whereas haploinsufficiency of other enzymes 
in the pathway cause porphyrias, due to accumulation of toxic 
heme precursors (see review by Puy et al., 2010). How heme is 
exported from mitochondria remains to be defined.
Mitochondrial iron uptake without the ability to use it for 
heme or Fe/S cluster biogenesis causes iron accumulation, 
because the excess import is not properly balanced by the 
export of products. Such mitochondrial iron depositions lead 
to the appearance of “ringed” sideroblasts (erythroblasts with 
perinuclear iron accumulations) and occur in conditions such 
as X-linked sideroblastic anemia due to ALAS2 deficiency or in 
the autosomal recessive deficiency of SLC25A38 (solute car-
rier family 25, member 38), a mitochondrial transporter likely 
involved in the import of ALA substrate glycine (Table S1). Ane-
mia and ringed sideroblasts also appear when proteins involved 
in Fe/S cluster biogenesis are defective, such as impairment of 
GLRX5 (glutaredoxin 5) (Ye et al., 2010) or the ATP-binding cas-
sette protein ABCB7, which leads to sideroblastic anemia with 
ataxia (Table S1).
Although erythroblasts consume large amounts of iron, they 
have to maintain safety mechanisms to avoid iron and/or heme 
excess: iron can be stored in ferritin or exported by ferroportin. 
Erythroblasts express a ferroportin messenger RNA (mRNA) 
isoform (1b) that lacks the 5′ IRE and thus evades potential 
translational repression by IRPs (see below) (Zhang et al., 
2009). This isoform is susceptible to hepcidin degradation and 
may endow erythroid precursors with a mechanism to respond 
to systemic iron availability. Additionally, erythroblasts have 
the capacity to export excess heme (for example, when globin 
synthesis is limiting). The proposed exporter, FLVCR (feline leu-
kemia virus subgroup C cellular receptor), is a multitransmem-
brane protein, a member of the major facilitator superfamily, 
and a receptor for a virus that causes severe aplastic anemia 
in cats. Accumulation of toxic heme at the proerythroblast 
stage can cause apoptosis, and mice with neonatal FLVCR 
deficiency develop severe hyperchromic, macrocytic anemia, 
reticulocytopenia, and a block in erythroid maturation at the 
proerythroblast stage (Keel et al., 2008).
Iron Recycling
Macrophages have to shoulder the lion’s share of the burden 
of maintaining adequate levels of plasma iron. Given that less 
than 10% of the daily iron needs are met by intestinal absorp-
tion, the rest is covered by macrophages that recycle iron inter-
nally. The amount of plasma iron is just over 10% of the amount 
used daily, which means that plasma iron is turned over many 
times each day.
Macrophages phagocytose aged or damaged erythrocytes 
and catabolize heme using hemoxygenase. NRAMP1 (natu-
ral resistance-associated macrophages protein 1), a divalent 
metal transporter homologous to DMT1, is expressed within 
phagolysosomal membranes and participates in iron export 
from phagocytic vesicles (Soe-Lin et al., 2009). Export of fer-
rous iron from macrophages occurs via ferroportin (Figure 1). 
Reflecting its central role in systemic iron homeostasis, fer-
roportin expression in macrophages is regulated at multiple 
levels: ferroportin transcription is induced by erythrophago-
cytosis and heme iron, its translation is regulated by the IRE/
IRP system, and its protein stability by hepcidin (see below). 
Ferroportin-mediated iron export is coupled to the function of 
the multicopper oxidase ceruloplasmin, a protein synthesized 
and secreted by the liver. Ceruloplasmin-deficient mice and 
humans show hepatocyte and macrophage iron accumulation. 
Aceruloplasminemia causes anemia (highlighting the critical 
role of iron release for erythropoiesis), diabetes, a late-onset 
disorder of the basal ganglia, and retinal degeneration (Table 
S1).
Systemic Iron Homeostasis: The Iron Hormone Hepcidin
Hepcidin has emerged as the central regulatory molecule of 
systemic iron homeostasis. It is a defensin family member with 
strong links to innate immunity. The bioactive, mature 25 amino 
acid peptide is generated from an 84 amino acid prepropeptide 
by furin cleavage. Hepcidin is secreted from hepatocytes and 
circulates in plasma bound to α2-macroglobulin (Peslova et al., 
2009). Hepcidin clearance occurs via the kidney or by codeg-
radation with ferroportin. Hepcidin forms a hairpin structure 
with four intramolecular disulfide bonds (Jordan et al., 2009) 
and exhibits modest antimicrobial activity in vitro, which has 
not yet been demonstrated in vivo.
Hepcidin binds to ferroportin, triggers its internalization, 
ubiquitination, and subsequent lysosomal degradation (Nem-
eth et al., 2004). Ferroportin binding is mediated by the N termi-
nus of the peptide; Jak2 (Janus kinase 2) has been reported to 
bind to the hepcidin-ferroportin complex and to phosphorylate 
ferroportin before internalization (De Domenico et al., 2009).
Iron Overload
Research into the molecular mechanisms that underlie heredi-
tary hemochromatosis in patients and murine models has been 
instrumental to decipher hepcidin regulation in mammals. 
Hereditary hemochromatosis is an autosomal recessive dis-
ease that leads to iron overload of the liver and other organs. 
Complications, which are preventable by iron depletion ther-
apies, can be fatal and include liver cirrhosis, cancer, diabe-
tes, hypogonadism, heart failure, and arthritis. Family studies 
implicate four genes in the disorder (Table S1): the most com-
mon type, which has a carrier frequency of ?1:8 in Caucasian 
populations, is due to a homozygous missense mutation of the 
HFE gene (C282Y) (Feder et al., 1996). Less common but clini-
cally more severe forms of hereditary hemochromatosis are 
caused by mutations of the TfR2, hemojuvelin (HJV ), or hepci-
din (HAMP) genes. All recessive forms of the disease represent 
molecular defects of hepatocytes and are caused by inappro-
priately low hepcidin expression (Figure 2A): the disease sever-
ity and the age of onset roughly correlate with the degree of 
hepcidin deficiency (see review by Camaschella, 2005).
HFE encodes a ubiquitously expressed major histocom-
patibility complex class 1-like molecule. The C282Y mutation 
abrogates β2-microglobulin binding and HFE surface expres-
sion; other HFE mutations are relatively rare. Hepcidin levels 
in patients may be normal, but are inadequately low for the 
degree of iron loading (Piperno et al., 2007; Ganz et al., 2008) 
and display a blunted response to acute oral iron challenges 
(Piperno et al., 2007). The penetrance of HFE mutations is low 
and clinical manifestations occur most commonly in middle 
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aged males, indicating the importance of environmental and/
or additional genetic factors for disease expression (Beutler et 
al., 2002).
Juvenile hereditary hemochromatosis due to mutations in 
the HAMP or HJV genes may lead to irreversible hypogonad-
ism, refractory heart failure, and even death in the second to 
third decades of life. Patients with HAMP or HJV mutations are 
phenotypically similar and have virtually undetectable hepci-
din levels. HJV is a glycophosphatidlyinositol-linked protein, 
homologous to repulsive guidance molecules, and mostly 
expressed in liver, skeletal muscle, and heart. HJV is a bone 
morphogenetic protein (BMP) coreceptor (Babitt et al., 2006) 
that is required to drive hepcidin transcription via SMAD pro-
teins (Figure 2A) (see below). HAMP mutations are extremely 
rare. Mice lacking HAMP and HJV recapitulate the organ iron 
loading observed in humans (Table S1).
Hereditary hemochromatosis due to TfR2 mutations may 
present early, but with a less severe phenotype than the juve-
nile form (see review by Camaschella, 2005). TfR2 is a type II 
transmembrane protein that binds transferrin with lower affin-
ity than TfR1 (Figure 2A). Targeted Tfr2 gene deletion in mice 
causes iron overload with low basal hepcidin levels (Table S1); 
similar observations have been reported in humans with TFR2 
mutations.
A dominant form of hereditary hemochromatosis is caused 
by missense mutations in ferroportin (Table S1). Ferropor-
tin is the only known cellular iron exporter and represents 
the “hepcidin receptor.” Mutations that reduce its membrane 
localization or its ability to export iron cause macrophage iron 
retention, normal/low plasma iron levels, and in some cases 
iron-restricted erythropoiesis. A hemochromatosis-like dis-
ease with high plasma iron and hepatocyte iron accumulation 
is caused by hepcidin-resistant ferroportin mutations either 
because hepcidin fails to bind ferroportin (C326S) or the inter-
nalization and degradation of ferroportin following hepcidin 
binding is impaired (Fernandes et al., 2009).
Hepcidin levels are also inappropriately low in “iron-loading 
anemias” in which erythropoietic signals suppress hepcidin 
transcription (Figure 2B) even when systemic iron load is high. 
Figure 2. Regulation of Hepcidin Expression
(A) Hepcidin regulation by systemic iron availability. High concentrations of 
transferrin-Fe2 (Tf-Fe2) displace HFE from TfR1 to promote its interaction with 
transferrin receptor 2 (TfR2). The HFE-TfR2 complex then activates hepcidin 
transcription via ERK/MAPK and bone morphogenetic protein (BMP)/SMAD 
signaling. The BMP coreceptor hemojuvelin (HJV) interacts with type I and 
type II BMP receptors (BMPR) at the plasma membrane to induce phospho-
rylation of receptor-activated SMAD (R-SMAD) proteins, and subsequent 
formation of active transcriptional complexes involving the co-SMAD factor 
SMAD4. This signaling is inhibited by soluble HJV (sHJV). TMPRSS6 physical-
ly interacts with HJV and causes HJV fragmentation. SMAD7 interferes with 
SMAD4-controlled hepcidin activation. Sequence motifs critical for SMAD-
mediated control of the hepcidin promoter are shown.
(B) Hepcidin regulation by erythropoietic signals. GDF15 and TWSG 1 are 
released by erythroid precursors to inhibit BMP/SMAD activation of hepcidin. 
This situation characterizes iron-loading anemias.
(C) Hepcidin regulation by inflammatory stimuli. Interleukin 6 (IL6) activates 
the Janus kinase (JAK)/ signal transducer and activator of transcription (STAT) 
signaling pathway and stimulates the hepcidin promoter via a STAT-binding 
motif close to the transcription start site. The BMP signaling pathway also 
contributes to the inflammatory response via SMAD4.
28 Cell 142, July 9, 2010 ©2010 Elsevier Inc.
The prototype of these anemias is β-thalassemia intermedia, 
characterized by transfusion-independent iron overload and 
low to absent hepcidin levels. Growth differentiation factor 15 
(GDF15) and twisted gastrulation 1 (TWSG1) released by eryth-
roblasts have been proposed to be involved in hepcidin sup-
pression (Tanno et al., 2007, Tanno et al., 2009). In patients with 
homozygous β-thalassemia or other anemias with ineffective 
erythropoiesis, elevated serum GDF15 correlates with dimin-
ished hepcidin levels and increased iron absorption.
Iron Deficiency
Iron (blood) losses and/or insufficient iron intake/absorption from 
dietary sources can cause iron deficiency that most commonly 
manifests as microcytic anemia. Likewise, inappropriately high 
hepcidin expression lowers plasma iron levels (due to dimin-
ished iron release by macrophages and lower iron absorption) 
and causes anemia. In this context, the common acquired ane-
mia of chronic diseases (ACD) and the genetic iron-refractory 
iron deficiency anemia (IRIDA) are most interesting.
Related to its evolutionary origin, hepcidin transcription is 
activated by inflammatory cytokines, especially interleukin 
6 (Figure 2C). Hypoferremia develops rapidly as a result of 
decreased macrophage iron release and represents a defense 
mechanism against (iron-dependent) pathogens. Excessive 
hepcidin production is also seen in patients with infections, 
malignancies, chronic kidney diseases, or any type of inflam-
mation. If prolonged, it leads to ACD. In rare cases, hepcidin can 
be expressed ectopically by hepatic adenomas, which results 
in microcytic anemia with some features of ACD (Weinstein et 
al., 2002), but this anemia is fully reversible after removal of the 
adenoma.
Patients with iron deficiency normally have low or undetect-
able levels of hepcidin. This is not the case in patients with 
IRIDA, who suffer from a microcytic anemia that is unrespon-
sive to oral and partially refractory to parenteral iron, because of 
inappropriately high hepcidin levels. IRIDA is caused by muta-
tions in TMPRSS6 (matriptase-2), a gene that encodes a pro-
tease that negatively regulates hepcidin expression (Du et al., 
2008) (see below). Interestingly genetic variants in TMPRSS6, 
frequent in the general population, may modulate the ability to 
absorb iron and to synthesize hemoglobin for maturing erythroid 
cells (Andrews, 2009). Whether TMPRSS6 variants may contrib-
ute to sporadic iron deficiency by increased hepcidin levels and 
decreased dietary iron absorption remains to be explored.
Hepcidin Regulation
Hepcidin expression in hepatocytes is regulated by multiple, in 
part opposing signals, including systemic iron availability (such 
as diferric transferrin, Tf-Fe2), hepatic iron stores, erythropoietic 
activity, hypoxia, and inflammatory/infectious states (Figure 2). 
These different regulatory inputs are integrated transcriptionally.
Regulation by Systemic Iron Availability
After the discovery of the biological relevance of hepcidin, 
important progress has been made toward understanding 
the molecules and pathways that control hepcidin expres-
sion in response to iron and the role of the membrane proteins 
mutated in hereditary hemochromatosis (HFE, HJV, and TfR2) 
in this process (Figure 2A).
HFE has been suggested to act as a bimodal switch 
between two sensors of the concentration of Tf-Fe2, TfR1, 
and TfR2, on the plasma membrane of hepatocytes (Gos-
wami and Andrews, 2006). This model is supported by the 
following findings: HFE binds the ubiquitously expressed 
TfR1 at a site that overlaps the transferrin binding domain, 
and Tf-Fe2 thus competes with HFE binding to TfR1. By con-
trast, TfR2 can bind both HFE and Tf-Fe2 simultaneously 
(Gao et al., 2009). Mice bearing an engineered TfR1 mutation 
with increased HFE binding show low hepcidin expression 
and systemic iron overload similar to HFE-deficient mice, 
suggesting that the TfR1 sequesters HFE to prevent its par-
ticipation in hepcidin activation. Conversely, mutations that 
abolish the HFE-TfR1 interaction or mice with increased HFE 
levels display elevated hepcidin expression and succumb 
to iron deficiency (Schmidt et al., 2008). Hepcidin activation 
by holotransferrin requires both HFE and TfR2 (Gao et al., 
2010). These observations support a model in which high 
concentrations of Tf-Fe2 displace HFE from TfR1 to pro-
mote its interaction with TfR2, which is further stabilized by 
increased Tf-Fe2 binding to the lower-affinity TfR2. The HFE-
TfR2 complex then activates hepcidin transcription. Future 
research is needed to establish the stoichiometry of the pro-
teins involved in this “Tf-Fe2-sensing complex” and to clarify 
whether HJV is part of it.
Although HFE and TfR2 clearly contribute to hepcidin acti-
vation, the BMP signaling pathway is quantitatively the most 
critical. By as yet only partially understood mechanisms, it 
integrates signals from the “Tf-Fe2-sensing complex” and the 
hepatocytic iron stores. Central to the latter is BMP6, which 
is positively regulated by iron. How BMP6 mRNA expression 
is activated by increased iron levels and repressed by iron 
deficiency requires further investigation. Bmp6 knockout mice 
show hepcidin deficiency and tissue iron overload (Andrio-
poulos et al., 2009; Meynard et al., 2009), although BMP2 
and BMP4 can also bind to HJV. BMP6 is thought to act in 
an autocrine manner analogous to its role in chondrocyte dif-
ferentiation (Grimsrud et al., 1999) to induce signaling via HJV, 
the BMP coreceptor that adapts BMP receptors for iron regula-
tion (Babitt et al., 2006). The BMP/HJV complex joins the type 
I (Alk2 and Alk3) and the type II (ACTRIIA) BMP receptors to 
induce phosphorylation of receptor activated SMAD (R-SMAD) 
proteins and subsequent formation of active transcriptional 
complexes involving the co-SMAD factor, SMAD4 (Wang et al., 
2005) (Figure 2A).
Two sequence motifs (the proximal BMP-RE1 and the distal 
BMP-RE2) of the hepcidin promoter are critical for transcrip-
tion via HJV, BMP6, and SMAD4 (Casanovas et al., 2009), 
and the promoter region that contains BMP-RE2 confers iron 
responsiveness to the hepcidin promoter (Truksa et al., 2007). 
Multiple lines of evidence highlight the importance of HJV/
BMP/SMAD signaling for hepcidin activation: (1) mice lacking 
HJV show attenuated R-SMAD phosphorylation in the liver 
(Babitt et al., 2006), (2) administration of BMP2 and BMP6 
to mice induces hepcidin mRNA and decreases serum iron 
levels, (3) BMP antagonists (such as dorsomorphin) inhibit 
hepcidin mRNA expression and increase serum iron levels 
(Yu et al., 2008), (4) liver-specific disruption of the co-SMAD4 
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causes severe iron overload with diminished hepcidin tran-
scription (Wang et al., 2005), and (5) the inhibitory iSMAD7 
potently suppresses hepcidin transcription in cellular models 
(Mleczko-Sanecka et al., 2010). Interestingly, R-SMAD phos-
phorylation is also attenuated in mice lacking HFE, suggest-
ing that HJV and HFE act together to activate hepcidin tran-
scription (Corradini et al., 2009; Kautz et al., 2009). Crosstalk 
between the BMP/SMAD and p38-MAPK signaling pathways 
activates hepcidin mRNA expression in response to Tf-Fe2 
in primary hepatocytes. Activation of p38-MAPK and Erk1/2 
depends on both HFE and TfR2, as this pathway is attenuated 
in mice lacking HFE or TFR2 and in double-knockout mice 
(Wallace et al., 2009).
Apart from mutations of the hepcidin gene itself, only HJV 
mutations lead to a near absence of hepcidin expression and 
the most severe form of hereditary hemochromatosis. Thus, 
HJV is central for hepcidin expression, and the point of con-
vergence of multiple regulatory inputs. The membrane-associ-
ated protease TMPRSS6 that is mutated in IRIDA (see above) 
physically interacts with HJV and cleaves HJV when both pro-
teins are expressed on the cell surface, suggesting that HJV 
is the major TMPRSS6 target for iron regulation (Silvestri et 
al., 2008a). Genetically, the combined deficiency of HJV and 
TMPRSS6 causes iron overload, suggesting that TMPRSS6 
acts upstream of HJV (Truksa et al., 2009, Finberg et al., 2010). 
Increased HJV surface expression has however yet to be con-
firmed in Tmprss6-deficient mice or IRIDA patients.
Furin-mediated cleavage releases HJV from cells to gener-
ate soluble HJV (sHJV), which antagonizes BMP-dependent 
hepcidin activation. Furin mRNA expression is regulated by 
iron and hypoxia, conferring another level of control (Silvestri 
et al., 2008b). Because of the high HJV expression in skeletal 
muscle, it is tempting to speculate that sHJV is released as a 
muscle signal in iron deficiency. Importantly, cleavage of HJV 
by other proteases does not seem to be redundant with that 
by TMPRSS6, as lack of TMPRSS6 activity causes iron defi-
ciency in humans and mice. Future work needs to address 
how TMPRSS6 expression and activity are regulated, and the 
relative contributions of TMPRSS6 and furin to the regula-
tion of HJV and systemic iron homeostasis need to be further 
defined.
Neogenin, a DCC (deleted in colorectal cancer) family mem-
ber, appears to stabilize HJV to enhance BMP signaling and 
hepcidin expression. Consistently, mice lacking neogenin 
exhibit hepatic iron overload, low hepcidin levels, and reduced 
BMP signaling (Lee et al., 2010).
Regulation by Erythropoietic Signals
Erythropoiesis requires considerable quantities of iron, and 
the inhibition of hepcidin expression by erythropoietic signals 
(Figure 2B) thus is of great physiological importance. None-
theless, the molecular mechanisms and factors responsible 
are still poorly understood. Hepcidin suppression in response 
to phlebotomy or hemolysis depends on intact erythropoietic 
activity in mouse models: irradiation and cytotoxic inhibition of 
erythropoiesis prevent hepcidin suppression (Pak et al., 2006). 
GDF15 and TWSG1 are both released by erythroid precursors. 
High doses of GDF15 are detectable in the serum of patients 
with ineffective erythropoiesis such as β-thalassemia (Tanno 
et al., 2007). Such pathological concentrations of GDF15 can 
suppress hepcidin transcription in cell models, but the under-
lying molecular mechanism has not yet been characterized. By 
contrast, lower GDF15 concentrations fail to suppress hepci-
din in cellular models and are apparently ineffective in patients 
with sickle cell anemia, myelodysplastic syndrome, and ACD. 
TWSG1 expression is increased in thalassemic mice, where it is 
produced during early erythroblast maturation. In cellular mod-
els, the BMP-binding protein TWSG1 inhibits BMP-dependent 
activation of Smad-mediated signal transduction that leads to 
hepcidin activation (Tanno et al., 2009). Correlations between 
TWSG1 expression, serum iron parameters, and hepcidin lev-
els have not yet been studied in human anemias.
Regulation by Hypoxia
Liver-specific stabilization of the hypoxia-inducible factor 1 
(HIF1) and HIF2 decreases hepcidin expression, and chemi-
cal HIF stabilizers can suppress hepcidin mRNA expression in 
hepatoma cells (Peyssonnaux et al., 2007). These findings have 
raised the possibility that iron-dependent prolyl hydroxylases 
involved in HIF degradation may act as hepatic iron sensors. 
Whether or not HIFs directly bind to the hepcidin promoter is 
currently controversial.
In vivo, hypoxia induces erythropoietin (EPO) synthesis, 
which in turn stimulates erythropoiesis. EPO injection into mice 
reduces hepcidin levels in a dose-dependent manner and can 
override signals that activate hepcidin expression. Even low 
dose EPO injections in human volunteers promptly decrease 
urinary excretion of hepcidin (Robach et al., 2009). Because 
experimental blockade of erythropoietic activity prevents its 
effect, EPO likely suppresses hepcidin by stimulation of eryth-
ropoiesis rather than more directly (Pak et al., 2006).
Regulation by Inflammatory and Stress Signals
The inflammatory cytokines IL1 and IL6 are both potent induc-
ers of hepcidin expression, a response whose clinical impor-
tance for ACD has been discussed above. IL6 activates the 
Janus kinase (JAK)/signal transducer and activator of tran-
scription (STAT) signaling pathway, which activates the hepci-
din promoter via a STAT-binding motif close to the transcription 
start site (Figure 2C) (Fleming 2007). The BMP signaling path-
way also contributes to the inflammatory response via SMAD4 
(Casanovas et al., 2009; Wang et al., 2005). Mice injected 
with lipopolysaccharide (LPS) augment hepcidin transcription 
even in the context of iron overload; likewise, LPS counter-
acts the diminished hepcidin expression in response to iron 
deficiency, suggesting that the two signals are integrated at 
the hepcidin promoter and that inflammatory and iron stores 
regulators operate independently rather than following a strict 
hierarchy (Huang, et al., 2009a). Hepcidin expression is also 
increased by endoplasmic reticulum (ER) stress. This stress 
response can be controlled by the transcription factor cyclic 
AMP response element-binding protein H (CREBH) (Vecchi et 
al., 2009) or by the stress-inducible transcription factors CHOP 
and C/EBPalpha (Oliveira et al., 2009). It has also been sug-
gested that increased hepcidin transcription and iron depriva-
tion may represent defense mechanisms against excessive cell 
proliferation and cancer, possibly by binding of the p53 tumor 
suppressor protein to a response element in the hepcidin pro-
moter (Weizer-Stern et al., 2007).
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Therapeutic Opportunities
The increasing understanding of the role of hepcidin in iron 
overload and deficiency (inclucing ACD) opens new therapeu-
tic avenues in a field that at present is essentially limited to 
iron depletion or substitution therapy. Both hepcidin agonists 
and antagonists would be useful drug prospects to treat iron-
related disorders.
Current treatment options for diseases hallmarked by 
insufficient hepcidin expression would be complemented by 
hepcidin agonists. A proof-of-principle study has shown that 
transgenic hepcidin expression in mice lacking HFE can pre-
vent iron overload (Nicolas et al., 2003). However, it is not clear 
whether hepcidin substitution (similar to insulin treatment of 
type 1 diabetes) would complement the current treatment of 
hereditary hemochromatosis with phlebotomy (or iron chela-
tors). However, small molecules to augment hepcidin synthesis 
(via transcription) or mimic its effects on ferroportin are attrac-
tive candidates for the treatment of thalassemias, other iron-
loading anemias, and the iron overload induced by hepatitis 
C infection.
Hepcidin antagonists would be useful for the treatment of 
patients with iron-restricted anemias as a consequence of hep-
cidin excess (e.g., ACD, IRIDA). Hepcidin depletion by neutralizing 
antibodies or by hepcidin small interfering RNAs (siRNAs) was 
shown to restore normal hemoglobin levels in a mouse model of 
anemia of inflammation when applied in combination with EPO 
(Sasu et al., 2010). Here, inhibitors of the stimulatory pathways for 
hepcidin transcription could offer one class of candidate com-
pounds. Agents like the BMP signaling inhibitor dorsomorphin 
(Yu et al., 2008) or sHJV, which decrease baseline expression 
of hepcidin in mice, might prevent iron-deficiency anemias due 
to excess hepcidin. Alternatively, one can envisage blocking the 
effect of hepcidin on its only known target ferroportin, at the level 
of binding or the downstream effects that it triggers.
Figure 3. Cell Biology of Iron Metabolism
A generic cell is depicted. Most cells acquire plasma iron via transferrin receptor 1 (TfR1)-mediated endocytosis of transferrin-bound iron. In endosomes, iron 
is freed from transferrin and reduced to Fe(II) by STEAP metalloreductases prior its release into cytosol via divalent metal transporter 1 (DMT1); transferrin and 
TfR1 return to the plasma membrane to be used for further cycles. DMT1 also functions in the apical absorption of dietary iron after reduction by DCYTB and 
possibly other ferrireductases. Other iron acquisition pathways are symbolized (e.g., acquisition of heme iron from red blood cells by macrophages). Iron uptake 
systems feed the so-called labile iron pool (LIP). The LIP is utilized for direct incorporation into iron proteins or iron transport to mitochondria via mitoferrin 
(Mfrn), where the metal is inserted into heme and Fe/S cluster prosthetic groups. Proteins promoting heme transport into and out of cells have been identified. 
The fraction of the LIP that is not utilized for metalation reactions can be exported via ferroportin, which works together with ferroxidases for iron loading onto 
transferrin, or stored in a nontoxic form in ferritin shells. Ferritin can be released into the extracellular milieu by unknown mechanisms and interact with specific 
receptors on the cell surface. Some cells also express a mitochondrial form of ferritin to protect the organelle against iron-induced toxicity. The size of the LIP 
is determined by the rate of iron uptake, utilization, storage, and export; these processes must be coordinately regulated to avoid detrimental iron deficiency 
and prevent iron excess.
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Cellular Iron Homeostasis: The IRE/IRP System
The maintenance of iron homeostasis by cells involves tasks 
that are very similar to those addressed at the systemic level: 
coordination of iron uptake, utilization, and storage to assure 
the availability of appropriate supplies and to prevent toxicity. 
Remarkably, the machinery and the mechanisms are entirely 
different. In contrast to systemic iron metabolism, cellular iron 
traffic also involves regulated iron excretion (Figure 3).
Cellular Iron Uptake
Tf-Fe2 is a major iron source for mammalian cells, which they 
take up via the high-affinity TfR1. The Tf-Fe2/TfR1 complex is 
internalized by clathrin-dependent endocytosis. Subsequent 
acidification of early endosomes triggers conformational 
changes in both transferrin and its receptor that promote the 
release of iron (Dautry-Varsat et al., 1983). The freed iron is 
then reduced to Fe(II) by members of the STEAP familly of 
metalloreductases (Ohgami et al., 2005, 2006) for transport 
into the cytosol via DMT1; thus, DMT1 plays a dual role in iron 
metabolism as an apical membrane protein of enterocytes to 
mediate systemic iron absorption as well as a ubiquitous endo-
somal protein involved in iron transfer from endosomes to the 
cytosol. Apo-transferrin and the TfR1 are then largely recycled 
to the cell surface. Optimal kinetics of the transferrin cycle are 
important for efficient acquisition of transferrin-bound iron and 
require the EXOC6 member of the exocyst, a protein complex 
involved in vesicular trafficking (Lim et al., 2005). Although TfR1 
is ubiquitously expressed, the transferrin cycle is particularly 
important for the massive iron delivery to erythroid precursors. 
Humans and mice lacking transferrin expression accumulate 
iron in nonhematopoietic tissues such as the liver (Table S1), 
and targeted disruption of the Tfr1 locus in the mouse shows 
that TfR1 is required for the differentiation of erythroid, lym-
phoid, and neuroepithelial cells, but it is dispensable for the 
development of other tissues, at least during fetal life. This 
implies that at least some cells can acquire iron independently 
of the transferrin cycle.
Biochemical and genetic studies support the existence of 
transferrin-independent routes of iron uptake. DMT1 was 
once thought to be responsible for non-transferrin-bound iron 
uptake by liver cells, but iron loading of DMT1-deficient mouse 
hepatocytes indicates that at least one alternative transferrin-
independent uptake pathway must exist (Gunshin et al., 2005); 
the metal transporter ZIP14 is a candidate for this (Liuzzi et al., 
2006), but awaits functional validation in vivo.
Under conditions of systemic iron overload, the L-type volt-
age-gated calcium channel mediates transferrin-independent 
iron entry into cardiomyocytes (Oudit et al., 2003); calcium 
channels may also play a role in iron delivery to neuronal cells 
(Gaasch et al., 2007). Interestingly, calcium channel block-
ers such as nifedipine mobilize liver iron and enhance urinary 
excretion in iron-loaded mice, probably by increasing DMT1-
mediated iron transport (Ludwiczek et al., 2007). These find-
ings suggest new therapeutic opportunities for the treatment 
of systemic iron overload. Receptor-mediated endocytosis 
of other forms of protein-bound iron represents an addi-
tional means for specific cell types to take up iron: lipocalin 
2-dependent endocytosis of an iron-laden siderophore via the 
SLC22A17 lipocalin receptor has been proposed to modulate 
the survival of kidney cells in culture (Devireddy et al., 2005), 
but the physiological relevance of this iron uptake pathway 
remains uncertain as lipocalin 2 knockout mice develop nor-
mally. Serum ferritin can enter cells via the Scara5 (scavenger 
receptor class A, member 5) and TIM-2 (T cell immunoglobu-
lin and mucin domain containing 2) ferritin receptors (Li et al., 
2009, Chen et al., 2005).
Finally, specialized cells are able to acquire iron in the form 
of heme. The nature of the enterocytic heme importer remains 
uncertain; SLC48A1 is the only bona fide heme import mol-
ecule identified so far (Rajagopal et al., 2008), and gene inac-
tivation in mice should help to evaluate its in vivo functions in 
mammals.
Cells also acquire heme indirectly. Macrophages obtain 
heme by phagocytosis and processing of dying red blood 
cells. In plasma, hemoglobin and free heme arising from intra-
vascular hemolysis are cleared by specific scavenger systems: 
hemoglobin forms a complex with haptoglobin that is delivered 
to reticuloendothelial cells via CD163-mediated endocytosis. 
Among other plasma molecules, free heme binds to hemopexin 
and the complex is endocytosed via the CD91 receptor pres-
ent on the surface of macrophages, hepatocytes, and other 
cell types. Thus, cells meet their iron needs via different uptake 
systems optimized to serve the specific cellular iron demands 
(Figure 3).
Cellular Iron Export
Iron export occurs from many cells including neuronal and 
erythroid cells, but it is particularly important in cells that 
maintain plasma iron levels. Such cells include macrophages 
and duodenal enterocytes, and in fetal develoment iron export 
is mediated by cells of the extraembryonic visceral endo-
derm (ExVE) and placental syncythiotrophoblasts. These cells 
express relatively high levels of ferroportin (SLC40A1), and the 
effects of targeted disruption of the Slc40a1 locus in the mouse 
reflects the unique, nonredundant functions of ferroportin in 
iron release from these cell types (Donovan et al., 2005). As 
mentioned above, ferroportin transports Fe(II) and acts in con-
cert with either of the ferroxidases hephaestin (enterocytes) 
or ceruloplasmin (other cell types) that facilitate iron extrac-
tion from the ferroportin channel and subsequent loading onto 
plasma transferrin (De Domenico et al., 2007). The fact that both 
ceruloplasmin and hephaestin are copper dependent explains 
the importance of the copper status for iron metabolism.
In addition to ferroportin-mediated release of elemental iron, 
cells appear to be able to export iron in the form of heme; over-
expression and viral interference studies suggest that FLVCR1 
could promote heme efflux. The physiological role of heme 
export remains unclear, but FLVCR1 is essential in the mouse 
and is required for proerythroblast differentiation and mac-
rophage heme iron recycling (Keel et al., 2008). A small fraction 
of cellular iron can also exit the cell bound to ferritin, but the 
mechanisms and physiological role of ferritin release remain to 
be better defined.
Cellular Iron Storage
Iron from the cytoplasmic “labile iron pool” (LIP) that is not uti-
lized for metalation reactions or exported is stored within the 
nanocavity of ferritin heteropolymers made of 24 subunits of 
heavy (FtH1) and light (FtL) chains (see review by Arosio and 
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Levi, 2010). Both ferritin subunits are ubiquitously expressed, 
but their expression ratios vary depending on the cell type 
and in response to stimuli such as inflammation or infection. 
FtH1 carries the ferroxidase activitiy that is necessary for iron 
deposition into the nanocage, while FtL facilitates iron nucle-
ation and increases the turnover of the ferroxidase site. Little is 
known about how iron is extracted from the LIP and delivered 
to ferritin. Poly(rC)-binding protein 1 (PCBP1), an RNA-binding 
protein mostly known for its role in posttranscriptional regula-
tion, is required for ferritin iron loading in cultured cells and 
can promote ferritin iron loading in vitro (Shi et al., 2008); future 
work will address whether PCBP1 is the metallochaperone 
responsible for ferritin mineralization in vivo.
Ferritin provides cells with a means to lock up excess iron in 
a redox inactive form to prevent iron-mediated cell and tissue 
damage; it also constitutes an iron store whose mobilization 
involves both proteasomal and lysosomal ferritin degradation. 
Ferritin is essential, as shown by the early embryonic lethal-
ity of FtH1 knockout mice (Ferreira et al., 2000). Mutations of 
the FtL 5′ IRE (see below) cause the dominant hyperferritine-
mia-cataract syndrome. C-terminal mutations of FtL cause 
hereditary ferritinopathy, an adult-onset autosomal dominant 
neurodegenerative disease characterized by the presence of 
ferritin inclusion bodies and iron deposition in the brain (Table 
S1).
Homopolymers of a nuclear gene-encoded H-type ferritin 
are present in mitochondria (see review by Arosio and Levi, 
2010). Akin to its cytosolic counterpart, mitochondrial ferritin 
(FtMt) is thought to protect the organelle against iron-mediated 
toxicity. In contrast to FtH1 and FtL, FtMt is not ubiquitously 
expressed; it has been detected in tissues such as the tes-
tis, heart, endocrine pancreas, and kidney, but not in spleen, 
gut, or liver. Another major difference between cytosolic and 
mitochondrial ferritins is that FtMt expression is not (directly) 
controlled by the IRPs (see below).
Regulation of Cellular Iron Metabolism
While key aspects of systemic iron metabolism are regulated 
transcriptionally (hepcidin expression) and posttranslationally 
(ferroportin function by hepcidin), cellular iron homeostasis is 
coordinately regulated posttranscriptionally by iron regulatory 
protein 1 (IRP1) and IRP2 (also known as ACO1 and IREB2, 
respectively) (Figure 4). The two orthologous RNA-binding pro-
teins interact with conserved cis-regulatory hairpin structures 
known as IREs, which are present in the 5′ or 3′ untranslated 
regions (UTRs) of target mRNAs. Either of the two IRPs inhibits 
translation initiation when bound to the single 5′ UTR IREs of 
ferritin H- or L-chain (iron storage), ferroportin (export), ALAS2 
(utilization), mitochondrial aconitase (ACO2), or hypoxia-induc-
ible factor 2α (HIF2α/EPAS1) mRNAs, whereas their binding 
to the multiple IRE motifs within the 3′ UTR of TFR1 (uptake) 
mRNA prevents its endonucleolytic cleavage and subsequent 
degradation (see reviews by Muckenthaler et al., 2008, and 
Recalcatti et al., 2010). The IRPs also appear to positively regu-
late DMT1 (uptake) mRNA expression via a single 3′ UTR IRE 
motif, but the molecular mechanism is not known. Single IRE-
like structures with restricted phylogenetic conservation have 
been identified in the 3′ UTR of the CDC14A (cell division cycle 
14 homolog A), HAO1 (hydroxyacid oxidase 1), and CDC42BPA 
(CDC42 binding protein kinase α)/MRCKa mRNAs, but their 
functional roles are not yet clear.
A canonical IRE is defined by both RNA sequence and struc-
ture and consists of an unpaired cytosine separated from a 
CAGUGN loop (where N = U, C, or A) by a 5 base pair upper 
stem plus a lower stem of variable length (Muckenthaler et al., 
2008); the IREs of the HIF2α and DMT1 mRNAs have a nonca-
nonical additional bulge on the 3′ strand of the upper stem. The 
high specificity and affinity of the IRP1/IRE interaction results 
from two spatially distant sites that establish multiple RNA-
protein contacts clustered around the terminal loop and the C 
bulge, respectively, of the IRE (Walden et al., 2006); sequence 
Figure 4. Regulation of Cellular Iron 
 Metabolism
In iron-deficient cells (right), iron regulatory protein 1 
(IRP1) or IRP2 bind to cis-regulatory hairpin struc-
tures called iron-responsive elements (IREs), present 
in the untranslated regions (UTRs) of mRNAs encod-
ing proteins involved in iron transport and storage 
(Muckenthaler et al., 2008). The binding of IRPs to 
single IREs in the 5′ UTRs of target mRNAs inhibits 
their translation, whereas IRP interaction with mul-
tiple 3′ UTR IREs in the transferrin receptor 1 (TfR1) 
transcript increases its stability. As a consequence, 
TfR1-mediated iron uptake increases whereas iron 
storage in ferritin and export via ferroportin decrease, 
thereby increasing the LIP. In iron-replete cells (left), 
the FBXL5 iron-sensing F-box protein interacts with 
IRP1 and IRP2 and recruits the SKP1-CUL1 E3 ligase 
complex that promotes IRP ubiquitination and deg-
radation by the proteasome; IRP1 is primarily subject 
to regulation via the assembly of a cubane Fe/S clus-
ter that triggers a conformational switch precluding 
IRE-binding and conferring aconitase activity to the 
holoprotein. IRPs also modulate the translation of 
the mRNAs encoding the erythroid-specific ALAS2 
heme synthesis enzyme, the mitochondrial aconitase 
(ACO2), and the HIF2α hypoxia-inducible transcrip-
tion factor. Single 3′ UTR IRE motifs are present in 
the DMT1 and CDC14A mRNAs, but their role and 
mechanism of function are not yet fully defined.
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variability of the upper and lower stems also influences IRP1 
binding affinity, potentially contributing to the graded response 
of IRE-controlled mRNAs to IRP regulation (Goforth et al., 
2010). Approaches based on mutagenesis and systematic 
evolution of ligands by exponential enrichment (SELEX) have 
yielded high-affinity RNA binders that are substantially differ-
ent from the canonical IRE (Henderson et al., 1994, Butt et al., 
1996), suggesting that the IRP regulon may extend beyond the 
current list of IRE-containing mRNAs.
IRP-binding to IREs responds to cellular iron levels (Figure 
4). In iron-replete cells, IRP2 (and apo-IRP1, see below) inter-
acts with the FBXL5 (F-box and leucine-rich repeat protein 5) 
adaptor protein that recruits a SCF (SKP1-CUL1-F-box) E3 
ligase complex, promoting IRP ubiquitination and subsequent 
degradation by the proteasome (Salahudeen et al., 2009, Vash-
isht et al., 2009); in iron-deficient cells, the FBXL5-dependent 
degradation of IRPs decreases. Iron regulation of IRP turnover 
involves a hemerythrin-like domain of FBXL5 that acts as an 
iron sensor: direct binding of iron to this domain stabilizes 
FBXL5 (hence IRPs are degraded), whereas FBXL5 is other-
wise degraded.
IRP1-binding to IREs is subject to an additional layer of 
regulation. In iron-replete cells, IRP1 (but not IRP2) ligates a 
cubane 4Fe-4S cluster that precludes IRE binding (Walden et 
al., 2006; Muckenthaler et al., 2008); remarkably, 4Fe-4S IRP1 
functions as a cytosolic aconitase and the protein is hence 
bifunctional. In iron-deficient cells, IRP1 loses its Fe/S cluster 
and aconitase activity and adopts its IRE-binding (apo-IRP1) 
conformation. The molecular details of this iron-regulated Fe/S 
cluster assembly/disassembly are not yet known, but disrup-
tion of critical components of Fe/S cluster biogenesis stimulate 
the IRE-binding activity of IRP1 (see review by Sheftel and Lill, 
2009). It is thus possible that the ratio of holo- to apo-IRP1 
depends primarily on mitochondrial iron availability and Fe/S 
cluster synthesis, whereas cytosolic iron sensing may primarily 
involve IRP2.
Genetic ablation of both IRPs in the mouse causes embry-
onic lethality (Smith et al., 2006, Galy et al., 2008). By contrast, 
animals lacking either protein are viable and fertile. IRP2 knock-
out mice show a mild microcytic anemia, a tendency toward 
increased neurodegeneration, and abnormal body iron distri-
bution (Cooperman et al., 2005, Galy et al., 2005). IRP1 knock-
out mice are asymptomatic under laboratory conditions, dem-
onstrating that the cytosolic aconitase activity is not essential 
(Meyron-Holtz et al., 2004a). Taken together, IRP expression is 
essential, but the two proteins are largely redundant.
Experiments with animals and cultured cells show that the 
two IRPs respond differentially to non-iron signals. For exam-
ple, hypoxic conditions inactivate IRP1 by favoring holo-IRP1 
formation (Meyron-Holtz et al., 2004b) while stabilizing IRP2 
as a result of the oxygen requirement for iron-mediated FBXL5 
degradation. Furthermore, reactive oxygen species selectively 
activate IRP1 by causing disassembly of Fe/S clusters, likely 
via a membrane-initiated signaling pathway (Pantopoulos and 
Hentze, 1998). Phosphorylation of IRP1 and IRP2 by specific 
kinases can also regulate their activity. Although the exact 
physiological and pathophysiological functions of the differ-
ential regulation of IRP1 and IRP2, respectively, remain to be 
determined, it could in principle allow cells to finely control iron 
metabolism over a wide range of conditions and to alter the set 
points of the two regulatory proteins independently from iron 
control.
Intracellular Iron Trafficking and Utilization
One of the least well understood problems in iron biology is how 
iron moves within cells. In the cytoplasm, iron is present in di-
iron centers directly bound to proteins such as ribonucleotide 
reductase, but most iron trafficks to mitochondria, where it is 
incorporated into bioactive heme and Fe/S cluster prosthetic 
groups. Recent work identifies 2,5 dihydroxybenzoic acid as 
the iron-binding moiety of a mammalian siderophore related 
to bacterial enterobactin. Disruption of its biosynthesis causes 
mitochondrial iron deficiency, implicating its importance for 
intracellular iron transport to mitochondria (Devireddy et al., 
2010). In erythroblasts, the main mitochondrial iron importer for 
heme and Fe/S cluster biogenesis is Mfrn1. Mfrn1 is required 
for primitive and definitive erythropoiesis (Shaw et al., 2006).
Iron management within mitochondria also remains poorly 
understood. The metal is inserted into protoporphyrin IX by 
ferrochelatase to form heme, or delivered to the Fe/S cluster 
biosynthetic machinery possibly by the iron chaperone frataxin 
(FXN), a matrix protein that is defective in patients with Frie-
dreich’s ataxia (Table S1) (for details on the biogenesis of Fe/S 
cluster proteins, see review by Sheftel and Lill, 2009).
Whether a fraction of elemental iron exits mitochondria is not 
known, but heme is exported from the organelle via a yet unde-
fined mechanism and incorporated into proteins throughout the 
cell. Likewise, Fe/S clusters are utilized in multiple subcellular 
compartments; whether they all originate from mitochondria 
is still debated as components of the Fe/S cluster assembly 
machinery have been detected in the cytosol and could pro-
mote extramitochondrial Fe/S cluster synthesis or repair (Tong 
and Rouault., 2006; Sheftel and Lill, 2009). The central role of 
mitochondria in Fe/S cluster metabolism is also underscored 
by the inner membrane protein ABCB7 that is required for 
the maturation of cytosolic but not mitochondrial Fe/S cluster 
proteins; how exactly ABCB7 contributes to the maturation of 
extramitochondrial Fe/S cluster proteins is not known, as its 
function has not yet been defined.
By making heme and Fe/S clusters, mitochondria represent 
the major subcellular site of iron utilization and as such play a 
central role in the control of cellular iron metabolism. The IRPs 
are essential to secure mitochondrial iron supplies and func-
tion in vivo (Galy et al., 2010). When Fe/S cluster biogenesis is 
impaired, iron accumulates in mitochondria, potentially harm-
ing the organelle. A current model of how mitochondria influ-
ence cellular iron metabolism posits that cells sense mitochon-
drial iron insufficiency via an Fe/S cluster-dependent factor 
and respond by increasing mitochondrial iron levels; a heme 
intermediate could also be involved given that mitochondrial 
iron loading also occurs in erythroid cells with heme deficiency 
stemming from mutations in ALAS2 or SLC25A38. Diversion of 
iron to mitochondria would deplete the cytosol, thereby stim-
ulating IRP binding to IREs; in addition, perturbation of Fe/S 
cluster metabolism would activate IRP1. This in turn increases 
cellular iron uptake (TfR1, DMT1) and diminishes iron storage 
(ferritin) and export (ferroportin), so that more iron becomes 
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available; IRPs protect mitochondria against detrimental iron 
deficiency (Galy et al., 2010), although additional regulatory 
pathways could contribute (Huang et al., 2009b).
In erythroid cells, IRP activation furthermore inhibits ALAS2 
translation and heme synthesis to avoid the accumulation of 
toxic metabolic intermediates until mitochondrial iron suffi-
ciency is restored. By contrast, impaired Fe/S cluster biogen-
esis with abnormally high IRP activity seems to maintain con-
stitutively high levels of iron, triggering mitochondrial iron (over)
loading and, as observed in erythroblasts with glutaredoxin 5 
deficiency, block ALAS2 expression and heme synthesis (Table 
S1). Whether and how mitochondria can protect themselves 
against iron overload remains to be elucidated.
Crosstalk between Cellular and Systemic Regulators
As described above, systemic and cellular iron homeostasis 
are maintained by distinct control systems: hepcidin/ferropor-
tin and IRE/IRP. It seems very likely that there is higher level 
coordination between these two systems, and future work will 
define in more detail how the two systems tango in harmony 
(Figure 5). Three interconnections have already been identi-
fied.
First, the ferroportin connection: The expression of ferro-
portin 1, which is critical for plasma iron levels, is subject to 
regulation by both systems: the systemic iron status is commu-
nicated posttranslationally via hepcidin, whereas intracellular 
iron availability regulates ferroportin synthesis via the 5′ UTR 
IRE of the ferroportin mRNA. Mice doubly deficient for IRP1 
and IRP2 in enterocytes are unable to limit ferroportin expres-
sion in these iron exporting cells, leading to cellular iron defi-
ciency. This shows that both control mechanisms are required 
to assure regulated iron export (Galy et al., 2008). The IRE/
IRP system has to protect the cells exporting iron against det-
rimental iron losses, whereas hepcidin protects the organism 
against systemic overload. The creation of ferroportin mouse 
mutants in which hepcidin and IRP-dependent regulation are 
dissociated may help to more clearly define the relative con-
tribution of the two regulatory systems to the control of cel-
lular iron export under different physiological and pathological 
conditions.
Second, the HIF2α connection: HIF2α mRNA is an IRP tar-
get (Sanchez et al., 2007), and the encoded transcription factor 
regulates DMT1 expression at the apical surface of duodenal 
enterocytes (Mastrogiannaki et al., 2009). Mice lacking intesti-
nal HIF2α have decreased expression of DMT1 and ferroportin 
and thus fail to promote iron absorption even upon lowering 
of hepcidin expression. How exactly hepcidin, HIF2α, and IRP 
activity depend on each other to assure adequate systemic 
iron supplies requires further research. Cross-breeding of 
mouse lines with tissue-specific ablations of IRPs, HIF2α, and/
or hepcidin may prove to be informative. It has also been dis-
cussed that hepcidin transcription may be controlled by HIF2α 
in response to hypoxia or iron deficiency.
Third, the TfR connection: Hepcidin expression is regulated 
by the signaling receptor TfR2 and the “switch factor” HFE 
that also binds to TfR1 in competition with plasma Tf-Fe2 (see 
above). TfR1 expression is promoted by high IRP activity. The 
equilibrium between the amount of plasma iron “sensing” TfR1 
and “signaling” TfR2 is thought to be important for hepcidin 
activation, and IRP activity may thus indirectly affect hepcidin 
expression by regulating TfR1 levels in hepatocytes.
Perspectives
The 1980s and 90s brought us the foundational discoveries 
in cellular iron metabolism and its regulation, and we are now 
just leaving a decade of research during which systemic iron 
metabolism has progressed from enigma to significant under-
standing. What lies ahead?
As discussed above, an urgent issue is to further unravel 
how systemic and cellular iron control mechanisms talk to each 
other. We should not lose sight of the fact that fundamental 
questions of the cell biology of iron remain unanswered. How 
does iron traffic inside cells, and what is the importance of the 
recently identified 2,5 dihydroxybenzoic acid-containing mam-
malian siderophore? How is iron (and Fe/S clusters and heme) 
incorporated into iron containing proteins? We also need to 
focus research efforts to a greater degree on iron metabolism 
of different organ systems and of cell-cell interactions. For 
example, little is known about how the kidney handles iron: iron 
undergoes glomerular filtration and reabsorption, which have 
important physiological and potentially therapeutic implica-
tions. Similarly, the nervous system poses grand challenges: 
For example, why does iron deficiency affect the central ner-
vous system, although hereditary hemochromatosis patients 
do not accumulate iron in the brain even in the presence of 
extremely high plasma and systemic iron levels? How do local 
alterations of iron metabolism contribute to neurodegenera-
tion, and can we devise strategies to prevent or ameliorate 
its course? What role do changes in iron metabolism play in 
Figure 5. Interplay between Systemic and Cellular Iron-Regulatory 
Systems
(Left) In hepcidin-producing cells (for example, hepatocytes), iron-regulatory 
proteins (IRPs) can influence Hepcidin gene regulation by modulating levels 
of transferrin receptor 1 (TfR1) and/or hypoxia-inducible factor 2α (HIF2α); 
the iron-responsive element (IRE)/IRP system may also impact on Hepcidin 
expression by changing intracellular iron levels (dashed line). 
(Right) Ferroportin expression is regulated by both hepcidin and IRPs. Fur-
thermore, IRPs can potentially exert a direct positive effect on iron uptake via 
divalent metal transporter 1 (DMT1) or TfR1, or an indirect negative effect via 
HIF2α repression.
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interactions between inflamed tissues and cells of the immune 
system? Responses to the latter questions will also have impli-
cations for common disorders such as atherosclerosis and 
cancer.
Increasingly, our quest to understand basic cell biological 
phenomena will be complemented by exploration of the iron 
biology of disease states. Progress in this area will help to 
devise new therapeutic concepts. The impressive progress 
that has been made during the past few years in unraveling 
the regulation of hepcidin expression and its function may well 
translate into new drugs to treat iron overload diseases and 
some forms of anemia.
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